Background: 5-Aminolevulinic acid (5-ALA)-fluorescence-guided resection of malignant glioma is well established in many neuro-oncology departments. In addition, the use of 5-ALA has been reported for cerebral metastases, meningioma, and spinal tumors. We report a case of a patient with a leptomeningeal spread of a K27M-mutated spinal anaplastic astrocytoma (World Health Organization° [WHO] III), which was detected by its faint 5-ALA-induced fluorescence.
Case Description: A 26-year-old female patient with an incomplete resection of a spinal astrocytoma (WHO II) at Th1-Th3 was treated with adjuvant combined radiotherapy/chemotherapy. After 4 years the patient suffered from a progressive paraplegia. Magnetic resonance imaging of the central nervous system showed no local progression of the spinal astrocytoma but an extensive disseminated leptomeningeal tumor formation. The cerebrospinal fluid of the patient obtained by lumbar puncture showed no indication of malignant cells in the cytopathologic examination. An open biopsy with preoperative administered 5-ALA with excision of the sensory nerve root from the cauda equina was performed. The biopsy showed a clearly light pink 5-ALA-induced fluorescence. The histopathologic examination confirmed a leptomeningeal spread of a K27M-mutated anaplastic astrocytoma (WHO° III) without R132H-IDH1 mutation.
Conclusions: Previous application of 5-ALA might intraoperatively help to visualize and identify leptomeningeal spread.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.wneu.2017.10.069 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Intrathecal pemetrexed in NSCLC patients with leptomeningeal metastasis.
Ecancermedicalscience
October 2024
Department of Medical Oncology, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400012, India.
Spread of lung cancer to the leptomeninges is rare and difficult to treat. Standard therapy comprises CNS-penetrant targeted agents with or without intrathecal chemotherapy. We performed a retrospective analysis of 16 patients with advanced NSCLC and leptomeningeal disease treated with intrathecal pemetrexed 50 mg.
View Article and Find Full Text PDFCurrent Evidence in the Systemic Treatment of Brain Metastases from Breast Cancer and Future Perspectives on New Drugs, Combinations and Administration Routes: A Narrative Review.
Cancers (Basel)
December 2024
Department of Medical Oncology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.
Breast cancer is the most frequently diagnosed neoplasm all over the world and the second leading cause of cancer death in women. Breast cancer prognosis has significantly improved in the last years due to the advent of novel therapeutic options, both in the early and in advanced stages. However, the spread of the disease to the brain, accounting for 15-30% of the metastatic diagnoses, is challenging, and its poor prognosis represents an unmet medical need, leading to deterioration of quality of life and causing morbidity and mortality.
View Article and Find Full Text PDFCase report: Two cases of leptomeningeal metastases in patients with metastatic urothelial carcinoma treated with enfortumab vedotin.
Front Oncol
November 2024
Department of Medicine, Medical Oncology Division, British Columbia (BC) Cancer, Vancouver Centre, University of British Columbia, Vancouver, BC, Canada.
Article Synopsis
- Leptomeningeal carcinomatosis is a rare metastatic pattern in genitourinary cancer, found in less than 0.1% of cases, and can occur even after initial treatments with enfortumab vedotin (EV).
- Two cases of metastatic urothelial cancer are presented: both patients initially showed positive responses to EV but later developed severe neurologic symptoms due to leptomeningeal metastases confirmed through imaging and cytology.
- The cases highlight an unusual progression pattern among patients treated with EV, suggesting the need for further investigation into this type of cancer spread.
Primary diffuse leptomeningeal glioblastoma: a case report and literature review.
J Neurooncol
December 2024
Department of Neurosurgery, University of Virginia, Charlottesville, VA, USA.
Purpose: Glioblastoma (GBM) that presents as leptomeningeal disease (LMD) is extremely rare and fatal. Limited data are available regarding incidence, clinical presentation, and management. Prognosis is poor and no treatment is known to improve survival.
View Article and Find Full Text PDFImaging-tracked progression of primary leptomeningeal gliomatosis: A case report.
Surg Neurol Int
November 2024
Department of Neurosurgery, University of Occupational and Environmental Health, Kitakyusyu, Japan.
Background: Primary leptomeningeal gliomatosis (PLG) is a rare neoplasm characterized by the diffuse spread of glial tumor cells throughout the leptomeninges without any evidence of a primary tumor source in the brain or spinal cord parenchyma. Here, we present a case of PLG potentially linked to prior interventional radiotherapy.
Case Description: The patient was a 75-year-old woman with a history of interventional radiology for a left internal carotid cavernous sinus fistula 13 years before presentation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!